Physician profile
Jason Smith
NPI 1457857765
$613.68
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $59.73 · 2022: $254 · 2023: $281 · 2024: $19.07.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $300.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $300.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $144.20 | 2022-2023 | Wegovy, Ozempic, Rybelsus |
| E.R. Squibb & Sons, L.L.C. | $111.72 | 2022 | |
| Abbvie INC. | $92.63 | 2022-2023 | |
| Pfizer INC. | $50.99 | 2022-2023 | |
| Cumberland Pharmaceuticals, INC. | $32.39 | 2021 | |
| Lilly USA, LLC | $31.00 | 2022-2023 | Mounjaro, Trulicity |
| Genentech USA, INC. | $27.34 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $25.75 | 2023 | Nuedexta |
| Jazz Pharmaceuticals INC. | $25.21 | 2022 | |
| Sanofi-Aventis U.S. LLC | $24.31 | 2023 | |
| Phathom Pharmaceuticals, INC. | $19.07 | 2024 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $16.08 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $12.99 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.